Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported sales exceed purchases by $3.6MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Saxena Nishant C | Chief Business Officer | Aug 11 '26 | Buy | $9.63 | 2,600 | $25,036 | 77,900 | Aug 12 04:30 PM |
| Cohen Yuval | Chief Executive Officer | Aug 07 '26 | Sale | $10.08 | 17,000 | $171,396 | 157,316 | Aug 10 04:30 PM |
| Moran Sean F. | Chief Financial Officer | Aug 07 '26 | Sale | $10.08 | 12,000 | $120,971 | 84,694 | Aug 10 04:30 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.